Pasithea Therapeutics KTTA
NASDAQ KTTA
$0.49 +0.08 (+18.98%)
At close: Oct 21, 2026 · 4:00 PM EDT

Pasithea Therapeutics (KTTA) EBITDA Margin (2022)

Updated

Pasithea Therapeutics' EBITDA Margin came in at -1677.80% for Q4 2022, up 78.33 percentage points from the prior quarter.

Analysis

Pasithea Therapeutics (KTTA) EBITDA Margin (2022) Analysis & Trends

For FY2022, Pasithea Therapeutics' EBITDA Margin was -2586.12%, up 27330.45 percentage points from FY2021.

  • Going back by year, EBITDA Margin was -29916.57% in FY2021.
  • Business Quant data shows KTTA's EBITDA Margin at -1756.14% (Q3 2022), -19150.08% (Q2 2022) and -17568.63% (Q1 2022) in the three quarters before Q4 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 35.95%
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 49.01%
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 6.02%
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 33.11%
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 46.01%
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -124.26%
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 39.16%
10 Pasithea Therapeutics 15.54 Mn -139.85 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 -1,677.80%
Sep 30, 2022 -1,756.14%
Jun 30, 2022 -19,150.08%
Mar 31, 2022 -17,568.63%
API Access

Pasithea Therapeutics EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=KTTA&period=max&api_key=YOUR_API_KEY